Search results for "cumulative"

showing 10 items of 299 documents

2020

(1) Background: Knowledge about predictors for the long-time patency of recanalized chronic total coronary occlusions (CTOs) is limited. Evidence from invasive follow-up in the absence of acute coronary syndrome (routine surveillance coronary angiography) is scarce. (2) Methods: In a monocentric-retrospective analysis, we obtained baseline as well as periprocedural data of patients undergoing routine invasive follow-up. We defined target vessel failure (TVF) as a combined primary endpoint, consisting of re-occlusion, restenosis, and target vessel revascularization (TVR). (3) Results: We included 93 consecutive patients (15.1% female) from October 2013 to May 2018. After a follow-up period o…

Acute coronary syndromemedicine.medical_specialtybiologybusiness.industrymedicine.medical_treatmentGeneral Medicine030204 cardiovascular system & hematologyRevascularizationmedicine.diseaseTroponin03 medical and health sciences0302 clinical medicineRestenosisInternal medicineCohortmedicineClinical endpointCardiologybiology.proteinCumulative incidence030212 general & internal medicinebusinessTIMIJournal of Clinical Medicine
researchProduct

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemothe…

2010

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). Patients and Methods From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy. Results Seventeen of 918 patients who achieved CR developed t-MN (10 with < 20% and seven with ≥ 20% of bone marrow blasts) after a median of 43 months from CR. Partial and…

Acute promyelocytic leukemiaAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAnthracyclinemedicine.medical_treatmentTretinoinGastroenterologyLeukemia Promyelocytic AcuteTretinoinRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCumulative incidenceAnthracyclinesProspective StudiesAgedChemotherapybusiness.industryIncidenceNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisSurgeryLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyFemaleBone marrowbusinessBone Marrow Neoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup …

2016

Abstract Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high remission and survival rates coupled with significantly reduced myelosuppression. Recent results of the APL0406 trial by the GIMEMA-AMLSG-SAL study groups showed that the combination of ATRA and arsenic trioxide (ATO) is superior to standard ATRA and chemotherapy (CHT) in front-line therapy of low/intermediate risk acute promyelocytic leukemia (APL). The implications of these results for the clinical practice of APL patients in Germany …

Acute promyelocytic leukemiaChemotherapyPediatricsmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyComplete remissionCell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenRegimenchemistry.chemical_compoundchemistryMedicineCumulative incidenceObservational studyArsenic trioxidebusinessneoplasmsBlood
researchProduct

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia - Updated Results of the Ital…

2014

Abstract Background: We recently showed that the combination of ATRA and arsenic trioxide (ATO) is at least not inferior and possibly superior to standard ATRA and chemotherapy (CHT) in the front-line management of low/intermediate risk APL (Italian-German APL 0406 trial; Lo-Coco et al., NEJM 2013). We report herein on the extended and final series of 276 patients (162 were in the previous report) with the last case being enrolled into the study in January 2013. Methods: The APL0406 study was a prospective, open-label, randomized intergroup trial conducted by the Italian GIMEMA and the German SAL and AMLSG study groups. Eligible patients were adults aged 18-<71 years with newly diagnosed…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtyChemotherapyAnthracyclinebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyOff-label usemedicine.diseaseBiochemistrychemistry.chemical_compoundchemistryInternal medicineCohortmedicineIdarubicinCumulative incidenceArsenic trioxidebusinessmedicine.drug
researchProduct

Predictability of early atopy by cord blood-IgE and parental history.

1997

Summary Background Atopic family history and cord blood IgE have been used as predictors of atopic disease in newborns for about 20 years, but at least for cord blood IgE the sensitivity has been shown to be very low. The objective of this paper was to evaluate whether parental history and cord blood-IgE were more accurate predictors for the appropriate atopic phenotypes in the infants rather than for any atopy. Methods A total of 1314 newborn infants was recruited in six German obstetric departments in 1990 and followed-up for 2 years. Four hundred and ninty-ninc (38%) were at high risk for atopy with at least two first degree atopic family members and/or elevated cord-blood IgE concentrat…

AdultHypersensitivity ImmediateAllergyPediatricsmedicine.medical_specialtyImmunologyImmunoglobulin EAtopyCohort StudiesPregnancyRisk FactorsGermanyImmunology and AllergyMedicineHumansCumulative incidenceProspective StudiesFamily historyAsthmaFamily Healthbiologybusiness.industryInfant NewbornInfantAtopic dermatitisImmunoglobulin Emedicine.diseaseFetal BloodPhenotypeCord bloodbiology.proteinFemalebusinessClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting

2016

Summary Pathogenic interactions between bacteria and cytomegalovirus (CMV) may potentially occur early after allogeneic stem cell transplantation (Allo-SCT). This possibility nevertheless has not been investigated in depth. This was a retrospective study that included 170 consecutive patients who underwent 173 Allo-SCTs. Both bacterial infection (most of which were bacteremic) and CMV DNAemia were detected in 78 Allo-SCTs (62.9%). In total, 51 and 32 episodes of bacterial infection preceded or occurred after CMV DNAemia detection, respectively. Both events were diagnosed concurrently in four Allo-SCTs. The cumulative incidence of bacterial infection (of any type) over the study period was c…

AdultMale0301 basic medicineAdolescent030106 microbiologyCongenital cytomegalovirus infectionCytomegalovirusBacteremiaYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansTransplantation HomologousCumulative incidence030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesRetrospective cohort studyBacterial InfectionsCmv dnaemiaMiddle Agedmedicine.diseaseCytomegalovirus infectionTransplantationBacteremiaCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellbusinessFollow-Up StudiesTransplant International
researchProduct

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct

Lifetime cumulative risk factors predict cardiovascular disease mortality in a 50-year follow-up study in Finland.

2015

Summary. Background. Systolic blood pressure, total cholesterol and smoking are known predictors of cardiovascular disease (CVD) mortality. Less is known about the effect of lifetime accumulation and changes of risk factors over time as predictors of CVD mortality, especially in very long follow-up studies. Methods. Data from the Finnish cohorts of the Seven Countries Study were used. The baseline examination was in 1959 and seven re-examinations were carried out approximately in five-year intervals. Cohorts were followed up for mortality until the end of 2011. Time-dependent Cox models with regular time-updated risk factors, time-dependent averages of risk factors and latest changes in ris…

AdultMaleLongitudinal studyTime FactorsEpidemiologyBlood PressureDiseaseBody Mass IndexSeven Countries StudyRisk FactorsMedicineHumansRisk factorExerciseFinlandAgedAged 80 and overta112business.industryProportional hazards modelSmokinglongitudinal studyAge FactorsGeneral Medicineta3142riskitekijätMiddle AgedmortalityCumulative riskBlood pressureCholesterolCardiovascular Diseasessydän- ja verisuonitauditbusinessBody mass indexDemographyFollow-Up StudiesInternational journal of epidemiology
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (N…

2017

International audience; BackgroundWhether the route of early feeding affects outcomes of patients with severe critical illnesses is controversial. We hypothesised that outcomes were better with early first-line enteral nutrition than with early first-line parenteral nutrition.MethodsIn this randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2 trial) done at 44 French intensive-care units (ICUs), adults (18 years or older) receiving invasive mechanical ventilation and vasopressor support for shock were randomly assigned (1:1) to either parenteral nutrition or enteral nutrition, both targeting normocaloric goals (20–25 kcal/kg per day), within 24 h after intubatio…

AdultMaleParenteral NutritionPediatricsmedicine.medical_specialtyTime FactorsCritical CareSecondary infectionEnteral feedingClinical nutritionEnteral administrationlaw.invention03 medical and health sciencesEnteral Nutrition0302 clinical medicineRandomized controlled triallaw[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyHumansVasoconstrictor AgentsMedicineCumulative incidenceHospital Mortality030212 general & internal medicineNutritional supportAgedAcute critical illnessbusiness.industryMalnutritionHazard ratioShock030208 emergency & critical care medicineGeneral MedicineLength of StayMiddle AgedInterim analysisRespiration ArtificialThe enteral route3. Good healthTreatment OutcomeParenteral nutritionFemalebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct